Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 12/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 11/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990481 | 0.83 | ADRB3 (0.56) | ADRB3ADRB2ADRB1L3MBTL1DNM1 | |
| SCHEMBL2999951 | 0.80 | ADRB2 (0.75) | ADRB3ADRB2ADRB1DNM1 | |
| SCHEMBL2990896 | 0.79 | ADRB3 (0.70) | ADRB3ADRB2ADRB1DNM1 | |
| SCHEMBL2992569 | 0.78 | ADRB3 (0.72) | ADRB3ADRB2ADRB1DNM1 | |
| SCHEMBL3000200 | 0.78 | ADRB3 (0.55) | ADRB3ADRB2ADRB1L3MBTL1DNM1 | |
| SCHEMBL2992698 | 0.76 | ADRB3 (0.67) | ADRB3ADRB2ADRB1L3MBTL1DNM1 | |
| SCHEMBL2989278 | 0.76 | ADRB3 (0.59) | ADRB3ADRB2ADRB1DNM1 | |
| SCHEMBL16550133 | 0.76 | MAPT (0.69) | ADRB3ADRB2ADRB1DNM1MAPT | |
| SCHEMBL2988364 | 0.76 | ADRB3 (0.55) | ADRB3ADRB2ADRB1L3MBTL1DNM1 | |
| SCHEMBL2983464 | 0.75 | ADRB3 (0.74) | ADRB3ADRB2ADRB1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | claimed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | claimed |
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | disclosed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | disclosed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | IL6, IL6ST, STAT3 | ADRB3 3238/4885ADRB2 4160/4885ADRB1 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.